Andrew W. Roberts
246 Clayton Rd
Melbourne, VIC 3168, Australia
Melbourne, VIC 3168, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 166 publications
Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.
Journal: Blood advances
Published: April 17, 2026
Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression.
Journal: Blood
Published: January 12, 2026
Myeloid/lymphoid neoplasms with eosinophilia and ZMYM2::FLT3 fusion: clinical, pathological and molecular clues to a cryptic diagnosis.
Journal: Pathology
Published: September 03, 2025
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.
Journal: HemaSphere
Published: June 06, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
Journal: Blood advances
Published: April 08, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.
Journal: Blood advances
Published: April 08, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.
Journal: Leukemia
Published: February 04, 2025
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancer.
Journal: Blood advances
Published: January 30, 2025
Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial.
Journal: The Journal of antimicrobial chemotherapy
Published: January 30, 2025
Last Updated: 09/26/2026